Table 2.

DILIsym predictions for telcagepant, MK-3207, and ubrogepant in a simulated patient population of healthy volunteers [63]

Compound	Dosing protocol	Simulated ALT > 3× ULN	Clinical ALT > 3× ULN
Telcagepant	280 mg BID 12 weeks	12.6% (36/285)	3.2% (8/253)
	140 mg BID 12 weeks	0% (0/285)	1.9% (5/258)
MK-3207	200 mg q2h, 2 daily doses (400-mg daily dose), for 14 days	3.5% (10/285)	42% (5/12) among individuals dosed for more than 1 week; most responding were given 600–900 mg per day
	300 mg q2h, 2 daily doses (600-mg daily dose), for 14 days	7% (20/285)
	450 mg q2h, 2 daily doses (900-mg daily dose), for 14 days	10.2% (29/285)
Ubrogepant	100 mg q2h, 4 days	0% (0/285)	N/A
	1000 mg q2h, 4 days	0% (0/285)	N/A
	100 mg QD, 8 days	0% (0/285)	N/A
	1000 mg QD, 8 days	0% (0/285)	N/A
	50 mg QD, 2 days on, 2 days off for 56 days, 28 total doses	0% (0/285)	N/A
	100 mg QD, 2 days on, 2 days off for 56 days, 28 total doses	0% (0/285)	0.8% 2/256

ALT alanine aminotransferase, BID twice daily, N/A not applicable, q2h every 2 hours, QD once daily, ULN upper limit of normal